An in-depth look at this medical topic, providing essential context for patients and caregivers.
General Medical Overview
Endometrial stromal sarcoma: A condition categorized under Gynecology, Urology & Reproduction.
Endometrial stromal sarcoma (ESS) is a rare uterine malignancy arising from endometrial stromal cells. Low-grade ESS is driven by specific gene fusions (JAZF1-SUZ12 most common) and has an indolent course with late recurrences. High-grade ESS (YWHAE-NUTM2 fusion) is more aggressive. Undifferentiated uterine sarcoma is the most aggressive type.
Typical Treatment Roadmap
Detection
Symptoms and initial checkup.
Diagnosis
Biopsy and clinical imaging.
Treatment
Therapy (Surgery, Chemo, etc.)
Monitoring
Follow-up and recovery.
Clinical Manifestation (Main Symptoms)
Clinically, the initial presentation of Endometrial stromal sarcoma often manifests with Fatigue, Pain and Bleeding.
Advanced Stage Signs (Warning)
Abnormal uterine bleeding, pelvic mass, pelvic pain, and late recurrences (even 10-20+ years for low-grade ESS).
Diagnostic Procedures
Endometrial biopsy/hysteroscopy, pelvic MRI, and histopathology with fusion gene testing (JAZF1-SUZ12 for low-grade, YWHAE-NUTM2 for high-grade).
Medical Risk Factors
No clearly established modifiable risk factors. Prior pelvic radiation has been associated in rare cases. No link to estrogen exposure clearly established.
Therapeutic Approach
Total hysterectomy with BSO (hormonal sensitivity makes oophorectomy important for low-grade ESS). Aromatase inhibitors (letrozole, anastrozole) for recurrent ER-positive low-grade ESS. Doxorubicin-based chemotherapy for high-grade ESS. Hormonal therapy is ineffective for high-grade and undifferentiated types.
Medical Breakthroughs & Hope
Low-grade endometrial stromal sarcoma has excellent outcomes and responds to hormonal therapy. Even late recurrences are typically manageable with aromatase inhibitors due to the tumor's hormone receptor positivity.
Prognosis & Efficacy51%
Low-grade ESS has excellent 5-year survival exceeding 90%, though late recurrences are characteristic. High-grade ESS: approximately 50-60%. Undifferentiated uterine sarcoma: approximately 25-40%.
Myth vs. Clinical Reality
Myth / Fiction
Uterine tumors are always fibroids.
Fact / Reality
While fibroids are overwhelmingly common, rare uterine malignancies like ESS exist. Atypical features on imaging or rapid growth should prompt evaluation.
Myth / Fiction
Late recurrence means the cancer is incurable.
Fact / Reality
Late recurrences of low-grade ESS are typically manageable with hormonal therapy, and many patients achieve prolonged disease control.
Frequently Asked Questions (FAQ)
Why is ovarian removal important?
Low-grade ESS is typically estrogen receptor-positive. Removing the ovaries (the main estrogen source) is therapeutic and reduces recurrence risk.
Why can it recur so late?
Low-grade ESS cells grow very slowly and can survive dormant for years. Recurrences 10-20 years after initial treatment are well-documented, requiring lifelong follow-up.
Is hormonal therapy effective?
For ER-positive low-grade ESS, aromatase inhibitors can effectively control recurrent disease for extended periods. This is a unique advantage of the hormonal sensitivity of this tumor.
How is it different from uterine fibroids?
ESS is a rare malignancy, while fibroids are very common benign tumors. Pathological examination distinguishes them. ESS may be found unexpectedly after surgery for presumed fibroids.
Is it hereditary?
No hereditary predisposition has been identified. The characteristic gene fusions are somatic (acquired) events.